| Citation: |
GU Y P, ZHU F. Research progress of anti-inflammation therapy and immunotherapy for acute pancreatitis[J]. Chin J Clin Med, 2025, 32(1): 120-124. DOI: 10.12025/j.issn.1008-6358.2025.20241425
|
At present, the incidence and mortality rate of severe acute pancreatitis is 15%-20% and about 20%, respectively, which can lead to local and systemic complications of patients and huge medical costs. The occurrence of acute pancreatitis is closely related to inflammatory response. This article reviews the progress of anti-inflammation therapy and immunotherapy of acute pancreatitis, aiming to provide reference for treatment in patients with acute pancreatitis.
| [1] |
DUNN J A, LI C, HA T, et al. Therapeutic modification of nuclear factor kappa B binding activity and tumor necrosis factor-alpha gene expression during acute biliary pancreatitis[J]. Am Surg, 1997, 63(12): 1036-1043;discussion 1043-1044.
|
| [2] |
MAKHIJA R, KINGSNORTH A N. Cytokine storm in acute pancreatitis[J]. J Hepatobiliary Pancreat Surg, 2002, 9(4): 401-410. DOI: 10.1007/s005340200049
|
| [3] |
KARKI R, KANNEGANTI T D. The ‘cytokine storm’: molecular mechanisms and therapeutic prospects[J]. Trends Immunol, 2021, 42(8): 681-705. DOI: 10.1016/j.it.2021.06.001
|
| [4] |
THOMAS A L, CASTELLANOS K, MANCINELLI G, et al. Activin A modulates inflammation in acute pancreatitis and strongly predicts severe disease independent of body mass index[J]. Clin Transl Gastroenterol, 2020, 11(5): e00152. DOI: 10.14309/ctg.0000000000000152
|
| [5] |
HEGYI P. Necrotic amplification loop in acute pancreatitis: pancreatic stellate cells and nitric oxide are important players in the development of the disease[J]. J Physiol, 2018, 596(14): 2679-2680. DOI: 10.1113/JP275930
|
| [6] |
WANG J H, WANG L C, ZHANG X F, et al. Cathepsin B aggravates acute pancreatitis by activating the NLRP3 inflammasome and promoting the caspase-1-induced pyroptosis[J]. Int Immunopharmacol, 2021, 94: 107496. DOI: 10.1016/j.intimp.2021.107496
|
| [7] |
TACKE F, RODERBURG C, BENZ F, et al. Levels of circulating miR-133a are elevated in sepsis and predict mortality in critically ill patients[J]. Crit Care Med, 2014, 42(5): 1096-1104. DOI: 10.1097/CCM.0000000000000131
|
| [8] |
WEI H P, ZHAO H, CHENG D L, et al. MiR-148a and miR-551b-5p regulate inflammatory responses via regulating autophagy in acute pancreatitis[J]. Int Immunopharmacol, 2024, 127: 111438. DOI: 10.1016/j.intimp.2023.111438
|
| [9] |
MUN S J, CHO E, KIM H K, et al. Enhancing acute inflammatory and sepsis treatment: superiority of membrane receptor blockade[J]. Front Immunol, 2024, 15: 1424768. DOI: 10.3389/fimmu.2024.1424768
|
| [10] |
JOSEPH ELMUNZER B, SCHEIMAN J M, LEHMAN G A, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis[J]. N Engl J Med, 2012, 366(15): 1414-1422. DOI: 10.1056/NEJMoa1111103
|
| [11] |
MACHICADO J D, MOUNZER R, PARAGOMI P, et al. Rectal indomethacin does not mitigate the systemic inflammatory response syndrome in acute pancreatitis: a randomized trial[J]. Clin Transl Gastroenterol, 2021, 12(11): e00415. DOI: 10.14309/ctg.0000000000000415
|
| [12] |
HUANG Z Y, MA X, JIA X T, et al. Prevention of severe acute pancreatitis with cyclooxygenase-2 inhibitors: a randomized controlled clinical trial[J]. Am J Gastroenterol, 2020, 115(3): 473-480. DOI: 10.14309/ajg.0000000000000529
|
| [13] |
LADD A M, CONWELL D, BURROUGHS T E, et al. Prior exposure to nonsteroidal anti-inflammatory drugs reduces the rate of organ failure and in-hospital mortality in acute pancreatitis[J]. Am J Med, 2022, 135(4): 471-477. e1.
|
| [14] |
CHEN Z P, HUANG H P, HE X Y, et al. Early continuous blood purification affects TNF-α, IL-1β, and IL-6 in patients with severe acute pancreatitis via inhibiting TLR4 signaling pathway[J]. Kaohsiung J Med Sci, 2022, 38(5): 479-485. DOI: 10.1002/kjm2.12497
|
| [15] |
RASCH S, SANCAK S, ERBER J, et al. Influence of extracorporeal cytokine adsorption on hemodynamics in severe acute pancreatitis: results of the matched cohort pancreatitis cytosorbents inflammatory cytokine removal (PACIFIC) study[J]. Artif Organs, 2022, 46(6): 1019-1026. DOI: 10.1111/aor.14195
|
| [16] |
HUBER W, ALGÜL H, LAHMER T, et al. Pancreatitis cytosorbents (CytoSorb) inflammatory cytokine removal: a prospective study (PACIFIC)[J]. Medicine (Baltimore), 2019, 98(4): e13044. DOI: 10.1097/MD.0000000000013044
|
| [17] |
SCHEINMAN R I, COGSWELL P C, LOFQUIST A K, et al. Role of transcriptional activation of Ⅰ kappa B alpha in mediation of immunosuppression by glucocorticoids[J]. Science, 1995, 270(5234): 283-286. DOI: 10.1126/science.270.5234.283
|
| [18] |
GLOOR B, UHL W, TCHOLAKOV O, et al. Hydrocortisone treatment of early SIRS in acute experimental pancreatitis[J]. Dig Dis Sci, 2001, 46(10): 2154-2161. DOI: 10.1023/A:1011902729392
|
| [19] |
DONG L H, LIU Z M, WANG S J, et al. Corticosteroid therapy for severe acute pancreatitis: a meta-analysis of randomized, controlled trials[J]. Int J Clin Exp Pathol, 2015, 8(7): 7654-7660.
|
| [20] |
VINE J, BERLIN N, MOSKOWITZ A, et al. Corticosteroids to Reduce Inflammation in Severe Pancreatitis (CRISP) protocol and statistical analysis plan: a prospective, multicentre, double-blind, randomized, placebo controlled clinical trial[J]. Contemp Clin Trials, 2024, 139: 107486. DOI: 10.1016/j.cct.2024.107486
|
| [21] |
YANG L, ZHAO Z B. Somatostatin plus ulinastatin in the treatment of severe acute pancreatitis and its effect on serum cytokine levels[J]. Evid Based Complement Alternat Med, 2022, 2022: 7223632.
|
| [22] |
ULUIŞIK D, KESKIN E, ÖZAYDIN T, et al. Ameliorative effects of the melatonin on some cytokine levels, NF-κB immunoreactivity, and apoptosis in rats with cerulein-induced acute pancreatitis[J]. Iran J Basic Med Sci, 2024, 27(3): 279-285.
|
| [23] |
JOHNSON C D, KINGSNORTH A N, IMRIE C W, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis[J]. Gut, 2001, 48(1): 62-69. DOI: 10.1136/gut.48.1.62
|
| [24] |
CHEN K L, LV Z Y, YANG H W, et al. Effects of tocilizumab on experimental severe acute pancreatitis and associated acute lung injury[J]. Crit Care Med, 2016, 44(8): e664-e677. DOI: 10.1097/CCM.0000000000001639
|
| [25] |
PRICE C C, ALTICE F L, SHYR Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes[J]. Chest, 2020, 158(4): 1397-1408. DOI: 10.1016/j.chest.2020.06.006
|
| [26] |
TOWNSEND M J, STEPHEN HODI F, GROVER S. Infliximab for steroid-refractory immune checkpoint inhibitor-induced acute pancreatitis[J]. ACG Case Rep J, 2023, 10(3): e01018. DOI: 10.14309/crj.0000000000001018
|
| [27] |
HARSHAVARDHAN R B, VINCENT P K, NAIR P, et al. Preventive effect of tacrolimus on patients with post-endoscopic retrograde cholangiopancreatography pancreatitis[J]. Clin Endosc, 2022, 55(5): 665-673. DOI: 10.5946/ce.2021.265
|
| [28] |
BAVA E P, GEORGE J, TARIQUE M, et al. Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models[J]. JCI Insight, 2022, 7(2): e141108. DOI: 10.1172/jci.insight.141108
|
| [29] |
CHELPURI Y, PABBATHI S, ALLA G R, et al. Tropolone derivative hinokitiol ameliorates cerulein-induced acute pancreatitis in mice[J]. Int Immunopharmacol, 2022, 109: 108915. DOI: 10.1016/j.intimp.2022.108915
|
| [30] |
GREER P J, LEE P J, PARAGOMI P, et al. Severe acute pancreatitis exhibits distinct cytokine signatures and trajectories in humans: a prospective observational study[J]. Am J Physiol Gastrointest Liver Physiol, 2022, 323(5): G428-G438. DOI: 10.1152/ajpgi.00100.2022
|
| [31] |
LIU N, HE J, HU X, et al. Acute necrotising pancreatitis: measurements of necrosis volume and mean CT attenuation help early prediction of organ failure and need for intervention[J]. Eur Radiol, 2021, 31(10): 7705-7714. DOI: 10.1007/s00330-021-07840-x
|
| [32] |
SCICLUNA B P, VAN VUGHT L A, ZWINDERMAN A H, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study[J]. Lancet Respir Med, 2017, 5(10): 816-826. DOI: 10.1016/S2213-2600(17)30294-1
|
| [33] |
ZHAO W J. Immune-related genes can serve as potential biomarkers for predicting severe acute pancreatitis[J]. Horm Metab Res, 2023, 55(10): 711-721. DOI: 10.1055/a-2105-6152
|
| [34] |
NEYTON L P A, ZHENG X Z, SKOURAS C, et al. Molecular patterns in acute pancreatitis reflect generalizable endotypes of the host response to systemic injury in humans[J]. Ann Surg, 2022, 275(2): e453-e462. DOI: 10.1097/SLA.0000000000003974
|
| [35] |
LEVENTOGIANNIS K, KYRIAZOPOULOU E, ANTONAKOS N, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial[J]. Cell Rep Med, 2022, 3(11): 100817. DOI: 10.1016/j.xcrm.2022.100817
|
| [36] |
GARAMI A, HEGYI P. Precision medicine in pancreatitis: the future of acute pancreatitis care[J]. Function (Oxf), 2023, 4(3): zqad015. DOI: 10.1093/function/zqad015
|
DownLoad: